Summit Therapeutics Inc. Common Stock (SMMT) Financials
Key financial figures for Summit Therapeutics Inc. Common Stock (Q2 2026).
Summit Therapeutics Inc. reported revenue of $0.00 for Q2 FY2026. The company posted a net loss of $215.7 million, or -$0.28 per share. Free cash flow for the period was -$168.7 million. The figures above are as filed, and the full income statement, balance sheet and cash flow history for Summit Therapeutics Inc. are on the SentiSense financials page.
- Revenue
- $0
- Net Income
- -$216M
- EPS
- $-0.28
- Total Assets
- $752M
- Operating Cash Flow
- -$168M
Recent quarters
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| Q2 FY2026 | $0 | -$216M | -$0.28 | -$169M | |
| Q1 FY2026 | $0 | -$189M | -$0.24 | -$93M | |
| Q4 FY2025 | $0 | -$219M | -$0.29 | -$76M | |
| Q3 FY2025 | $0 | -$232M | -$0.31 | -$69M | |
| Q2 FY2025 | $0 | -$412M | -$0.56 | -$49M |
Recent fiscal years
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| FY2025 | $0 | -$1.1B | -$1.44 | -$240M | |
| FY2024 | $0 | -$177M | -$0.25 | -$114M | |
| FY2023 | $0 | -$482M | -$0.78 | -$61M |
Frequently asked questions
What was Summit Therapeutics Inc.'s revenue last quarter?
Summit Therapeutics Inc. reported revenue of $0.00 for Q2 FY2026.
Is Summit Therapeutics Inc. profitable?
Not in its most recent reported period. Summit Therapeutics Inc. reported a net loss of $215.7 million for Q2 FY2026.
How much free cash flow did Summit Therapeutics Inc. generate?
Summit Therapeutics Inc. generated free cash flow of -$168.7 million in Q2 FY2026, after capital expenditure.
Full income statement, balance sheet and cash flow for Summit Therapeutics Inc. Common Stock on SentiSense, with up to forty quarters and twenty fiscal years of history.